Neurotech Pharmaceuticals, Inc.: FDA Approves Neurotech's ENCELTO, First for Macular Telangiectasia Type 2

Neurotech Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved ENCELTO for the treatment of Macular Te